SCHEMBL4132974

SCHEMBL4132974

CN(CC(c1ccc(Cl)cc1)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1)C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 2/20 0.44
USP30 Q70CQ3 2/20 0.42
BACE1 P56817 1/20 0.39
BACE2 Q9Y5Z0 1/20 0.39
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
F11 P03951 4/20 0.35
F2 P00734 3/20 0.35
PRSS1 P07477 2/20 0.35
PRSS2 P07478 2/20 0.35
PRSS3 P35030 2/20 0.35
ESR2 Q92731 1/20 0.35
DGAT1 O75907 1/20 0.35
LIPG Q9Y5X9 3/20 0.34
LPL P06858 2/20 0.34
P4HB P07237 1/20 0.34
F10 P00742 1/20 0.34
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2559781 0.84 AAK1 (0.49) AAK1USP30BACE1BACE2PRMT5
SCHEMBL2554305 0.84 AAK1 (0.49) AAK1USP30BACE1BACE2PRMT5
SCHEMBL2557356 0.84 AAK1 (0.49) AAK1USP30BACE1BACE2PRMT5
SCHEMBL15092162 0.83 AAK1 (0.48) AAK1USP30BACE1BACE2PRMT5
SCHEMBL4130129 0.79 KMT2A (0.41) AAK1
SCHEMBL25142321 0.77 AAK1 (0.47) AAK1USP30BACE1BACE2PRMT5
SCHEMBL12170334 0.77 AAK1 (0.45) AAK1USP30BACE1BACE2PRMT5
SCHEMBL2565928 0.77 AAK1 (0.47) AAK1USP30BACE1BACE2PRMT5
SCHEMBL2565930 0.77 AAK1 (0.47) AAK1USP30BACE1BACE2PRMT5
SCHEMBL29840307 0.77 AAK1 (0.47) AAK1USP30BACE1BACE2PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090253718-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED (GB) 2009-10-08 US disclosed
US-20090253718-A1 Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED (GB) 2009-10-08 US disclosed
US-20090099213-A1 Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 US disclosed
US-20090099213-A1 Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 US disclosed
EP-2016077-A2 PHARMACEUTICAL COMPOUNDS Astex Therapeutics Limited (GB) 2009-01-21 EP disclosed
WO-2007125315-A2 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2007-11-08 WO disclosed
EP-1812003-A1 ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS Astex Therapeutics Limited (GB) 2007-08-01 EP disclosed
WO-2006046023-A1 ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253718-A1 Pharmaceutical Compounds GRK3, CNKSR1, CSNK1G3 AAK1 1895/4885USP30 3785/4885BACE1 2579/4885
US-20090099213-A1 Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors OXSR1, CDK1, CDK3 AAK1 318/4885USP30 3754/4885BACE1 3082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.